The proposed research is intended to investigate the mechanism of the metabolic stereoisomeric inversion of chiral pharmaceuticals in the body. The bioactivation of the inactive enantiomer in the racemic drugs via stereoisomeric inversion may result in severely adverse consequences due to the enhanced toxicity, especially for the elderly and patients with metabolic disorders. This phenomenon of chiral inversion has been commonly observed in the 2-arylpropionic acids which are important therapeutic agents for musculoskeletal disorders, but the mechanism as well as the involved enzyme system remains unclear. The objectives of this proposed investigation are to verify the inversion mechanism, to identify the enzyme system, and to carry out the pharmacological evaluation of individual 2- arylpropionic acids at the molecular level. Furthermore, this research will be extended to explore the metabolic inversion of other important chiral pharmaceutical such as beta-adrenergic blockers. In the elucidation of inversion mechanism, chiral tritium-labeled 2- arylpropionic acids will be synthesized and exposed to the homogenate of the liver and other organs of different animals. From the cofactor requirements and tritium release experiments, the mechanism can be unambiguously verified. Rat, rabbit, and guinea-pig will be used to compare the inter-species differences in this biotransformation. The isomerization enzyme system(s) will be purified using the combined techniques of conventional and affinity chromatographies. Various 2- arylpropionic acids, especially those which exhibit significant adverse effects will be examined using the purified enzyme system. To further extrapolate our experimental data to humans, cultured cells from different human organs will be used to evaluate the significance of this metabolic inversion in the human body. These proposed experiments will provide us important kinetic information, so that safer drugs such as alpha-deutero- or alpha-fluoro-derivative of 2-arylpropionic acids can be rationally designed. Similar approaches will be take to scrutinize the metabolic inversion of beta-adrenergic blockers.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29GM039236-05
Application #
2179706
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1989-04-01
Project End
1995-03-31
Budget Start
1993-04-01
Budget End
1995-03-31
Support Year
5
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Rhode Island
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
135531015
City
Kingston
State
RI
Country
United States
Zip Code
02881
Chen, C Y; Pang, V F; Chen, C S (1996) Pathological and biochemical modifications of renal function in ibuprofen-induced interstitial nephritis. Ren Fail 18:31-40
Chen, C Y; Chen, C S (1995) Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Br J Clin Pharmacol 40:67-72
Chen, C Y; Chen, C S (1994) Stereoselective disposition of ibuprofen in patients with renal dysfunction. J Pharmacol Exp Ther 268:590-4
Chen, C Y; Pang, V F; Chen, C S (1994) Assessment of ibuprofen-associated nephrotoxicity in renal dysfunction. J Pharmacol Exp Ther 270:1307-12
Shieh, W R; Chen, C S (1993) Purification and characterization of novel ""2-arylpropionyl-CoA epimerases"" from rat liver cytosol and mitochondria. J Biol Chem 268:3487-93
Shieh, W R; Gou, D M; Liu, Y C et al. (1993) A 13C NMR study on ibuprofen metabolism in isolated rat liver mitochondria. Anal Biochem 212:143-9
Chen, C S; Shieh, W R; Lu, P H et al. (1991) Metabolic stereoisomeric inversion of ibuprofen in mammals. Biochim Biophys Acta 1078:411-7
Chen, C Y; Lu, P H; Chen, C S (1991) Metabolic inversion of stereoisomeric ibuprofen in man. J Formos Med Assoc 90:437-42
Chen, C S; Chen, T; Shieh, W R (1990) Metabolic stereoisomeric inversion of 2-arylpropionic acids. On the mechanism of ibuprofen epimerization in rats. Biochim Biophys Acta 1033:1-6